In this study, we demonstrated that BM-V reduced plasma FGF21 levels and hepatic FGF21 content, and attenuated HFD-induced liver steatosis, while BM-V also significantly enhanced peripheral insulin sensitivity. The gene discussed is FGF21; the disease is Hepatic steatosis.